Get the Stockscreener App
223.32
0.29%
-0.66
After Hours:
222.50
-0.82
-0.37%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $223.32, with a volume of 5.40M.
It is down -0.29% in the last 24 hours and down -4.25% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$223.98
Open:
$223.685
24h Volume:
5.40M
Relative Volume:
0.92
Market Cap:
$394.69B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
168.51
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
-1.22%
1M Performance:
-4.25%
6M Performance:
+16.06%
1Y Performance:
+28.95%
1-Day Range:
$221.10
$223.82
1-Week Range:
$220.23
$226.12
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Women’s Healthcare Market Worth USD 46.76 Billion by 2033 Driven by Rising Demand for Reproductive, Preventive, and Digital Health Solutions – SNS Insider - GlobeNewswire Inc.
Assessing AbbVie (ABBV) Valuation After HSBC Upgrade, Strong Earnings, and Dividend Hike - Yahoo Finance UK
My Top 3 Healthcare Stocks to Buy in 2026 - Finviz
AbbVie Inc. $ABBV Shares Acquired by Curi Capital LLC - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Engineers Gate Manager LP - MarketBeat
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Sells 59,257 Shares of AbbVie Inc. $ABBV - MarketBeat
Bridgeway Capital Management LLC Purchases Shares of 110,140 AbbVie Inc. $ABBV - MarketBeat
Bellevue Group AG Boosts Stock Position in AbbVie Inc. $ABBV - MarketBeat
Benjamin Edwards Inc. Grows Stock Position in AbbVie Inc. $ABBV - MarketBeat
Ameriprise Financial Inc. Sells 3,127,890 Shares of AbbVie Inc. $ABBV - MarketBeat
Adage Capital Partners GP L.L.C. Lowers Position in AbbVie Inc. $ABBV - MarketBeat
Is AbbVie stock too cheap to ignore at today's price? - MSN
AbbVie Stock (ABBV) After-Hours Update: What Happened on Dec. 12, 2025—and What to Watch Before the Next Market Open - ts2.tech
ABBV Stock News: Lenz Therapeutics Faces Setback with FDA Report - GuruFocus
Morgan Stanley Maintains Overweight Rating on ABBV, Raises Price Target to $269 | ABBV Stock News - GuruFocus
Morgan Stanley Adjusts Price Target on AbbVie to $269 From $261, Maintains Overweight Rating - marketscreener.com
AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock - Finviz
Treasurer of the State of North Carolina Sells 27,645 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by Quantinno Capital Management LP - MarketBeat
Hamilton Capital LLC Cuts Holdings in AbbVie Inc. $ABBV - MarketBeat
Peapack Gladstone Financial Corp Acquires 20,164 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Nebula Research & Development LLC - MarketBeat
Canada Pension Plan Investment Board Has $466.58 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Diversify Advisory Services LLC Purchases 10,883 Shares of AbbVie Inc. $ABBV - MarketBeat
Alliancebernstein L.P. Increases Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie Stock (ABBV) Weekly Update & Week-Ahead Outlook: Analyst Upgrades, Pipeline Catalysts, and Key Levels — Updated Dec. 12, 2025 - ts2.tech
Hot Picks: Large-cap health care stocks to watch for dividend growth - BNN Bloomberg
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts - ts2.tech
Is AbbVie Stock Too Cheap to Ignore at Today's Price? - sharewise.com
Botox maker quietly launches plan to fend off rivals - Yahoo Finance
'This is a great opportunity to get, what we call, a dividend growing stock': Nesbitt on Abbvie Inc. - BNN Bloomberg
$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players - Yahoo Finance Singapore
Glenview Trust co Has $78.24 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth - The Globe and Mail
Scotiabank Sticks to Their Buy Rating for AbbVie (ABBV) - The Globe and Mail
CIBC Asset Management Inc Has $59.11 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265 - Finviz
AbbVie: Unique Mix Of Growth And Value (NYSE:ABBV) - Seeking Alpha
ASH 2025: AbbVie and Genmab’s Epkinly sets new standard in second-line FL - Yahoo Finance
AbbVie upgraded, Biogen downgraded as HSBC reflects on 2026 in pharma - MSN
AbbVie upgraded, Biogen downgraded at HSBC (BIIB:NASDAQ) - Seeking Alpha
Crohn’s Disease Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | AbbVie, Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH - Barchart.com
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More - Yahoo Finance
AbbVie Stock (ABBV) Opinions on Analyst Upgrade and Pipeline Developments - Quiver Quantitative
Intact Investment Management Inc. Sells 8,200 Shares of AbbVie Inc. $ABBV - MarketBeat
Here Are Wednesday's Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More - 24/7 Wall St.
AbbVie Inc. $ABBV Shares Sold by Integrated Investment Consultants LLC - MarketBeat
This AbbVie Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix… - marketscreener.com
HSBC Upgrades AbbVie to Buy From Hold, Adjusts Price Target to $265 From $225 - marketscreener.com
Investment Management Corp of Ontario Has $19.88 Million Position in AbbVie Inc. $ABBV - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):